FIB-4 Score as a Predictor of Eligibility for Elastography Exam in Patients with Polycystic Ovary Syndrome.

Biomedicines

Department of Internal, Autoimmune and Metabolic Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-751 Katowice, Poland.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Polycystic ovary syndrome (PCOS) and metabolic dysfunction-associated steatotic liver disease (MASLD) are common co-morbidities in women of reproductive age. PCOS is highly heterogeneous and is, therefore, divided into four phenotypes. MASLD leads to numerous systemic complications. Studies to date have shown an association between PCOS and MASLD. This study was designed to compare the FIB-4 score (based on age, alanine aminotransferase, aspartate aminotransferase and platelet count) and the results of shear wave elastography in assessing the risk of developing MASLD by patients with PCOS divided by phenotypes. The study enrolled 242 women age 18-35 years with PCOS diagnosed according to Rotterdam criteria, hospitalized at the Department of Gynaecological Endocrinology of the University Clinical Centre in Katowice. The study subjects were assigned to phenotypes A to D. Clinical and biochemical assessments were performed (including androgens and metabolic parameters), and the FIB-4 index was calculated. Liver fibrosis was evaluated by shear wave elastography. To balance the group sizes of phenotypes, oversampling with replacement was applied (PROC SURVEYSELECT, SAS), increasing the number of observations for phenotypes B, C, and D fivefold. Statistical analyses were performed based on data distribution (Shapiro-Wilk test), using ANOVA or the Kruskal-Wallis test with Dunn's correction. Statistical significance was set at < 0.05. The FIB-4 score was the highest in phenotype B patients (0.50 ± 0.15), and the lowest in phenotypes A and C (0.42 ± 0.14). The highest rate of positive elastography findings was recorded in phenotype A patients (34.7%) and the lowest in phenotype C group (13.5%). Significant differences between the phenotypes were also found in terms of androgen levels, insulin, HOMA-IR, and the lipid profile. Among patients with positive elastography, the highest FIB-4 scores were recorded in phenotype C group (0.44 ± 0.06), but the differences between the phenotypes were not statistically significant. The FIB-4 score was the highest in phenotype B patients and differed significantly from phenotypes A, C and D. In the elastography exam, the fibrosis index was statistically significantly higher in phenotype A compared to other phenotypes. No correlation was detected between the FIB-4 index and positive elastography. The findings suggest that the FIB-4 index may be used for MASLD screening, but its usefulness as a predictor of eligibility for elastography requires more research.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12383516PMC
http://dx.doi.org/10.3390/biomedicines13081878DOI Listing

Publication Analysis

Top Keywords

fib-4 score
16
phenotype patients
12
positive elastography
12
phenotypes
10
fib-4
8
predictor eligibility
8
elastography
8
eligibility elastography
8
elastography exam
8
polycystic ovary
8

Similar Publications

The coexistence of chronic hepatitis B (CHB) and metabolic dysfunction-associated liver disease (MASLD) gained recognition, but the diagnostic performance of non-invasive markers regarding it remains underexplored. This study aimed to evaluate the utility of the FIB-4 index for fibrosis prediction in CHB patients and investigate its performance in the distinct subgroup of CHB-MASLD. A prospective study from 2021 to 2022 included 109 CHB and 64 CHB-MASLD patients.

View Article and Find Full Text PDF

Non-alcoholic fatty liver disease (NAFLD), now termed metabolic dysfunction-associated steatotic liver disease (MASLD), is increasingly implicated as a key risk factor for cardiovascular disease (CVD). However, its independent contribution remains debated due to confounding metabolic factors and methodological heterogeneity. This review aims to synthesize evidence on the association between NAFLD/MASLD and cardiovascular outcomes, focusing on the influence of liver fibrosis and metabolic dysfunction.

View Article and Find Full Text PDF

Associations of PFOA and PFOS exposure with liver injury: Evidence from Two Population Studies and integrative adverse outcome pathway analysis.

Environ Pollut

September 2025

Department of Occupational and Environmental Health, State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Rd, Wuhan, 430030, Hubei, China. Electronic address:

Perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) are representatives of perfluoroalkyl substances (PFAS) that could persist in the environment and concentrated in animal livers. However, epidemiological studies on the associations of PFOA/PFOS exposure with liver injury in women are limited, with mechanisms not fully understood. This study aimed to clarify these associations and explore possible mechanisms.

View Article and Find Full Text PDF

Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with substantial clinical and economic burden. Fibrosis detection is key to disease management, but biopsy-defined staging is invasive, expensive, and associated with complications. We evaluated healthcare resource utilization (HCRU) and costs by disease stage using biopsy-defined staging and fibrosis-4 (FIB-4; a simple, well-validated, non-invasive tool for assessing fibrosis severity), and compared their utility for predicting long-term outcomes in MASLD.

View Article and Find Full Text PDF

The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing, particularly among young adults, posing significant long-term health risks. Early identification of at-risk individuals is crucial for timely intervention and prevention of liver fibrosis. This study aimed to evaluate the prevalence of MASLD in young adults aged 18-30 years and assess the utility of noninvasive fibrosis scores (fibrosis 4 index, AST-to-platelet ratio index [APRI], Hepamet fibrosis score) in risk stratification.

View Article and Find Full Text PDF